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Patients with similar tumor types can have markedly dif-
ferent responses to the same therapy. The development
of new treatments would benefit significantly, therefore,
from the introduction of imaging methods that allow an
early assessment of treatment response in individual
patients, allowing rapid selection of the most effective
treatment [1]. We have been developing methods for
detecting the early responses of tumors to therapy. This
has included a targeted MRI contrast agent for detecting
tumour cell death [2] and MR imaging of tumor cell
metabolism using hyperpolarized 13C-labelled cellular
metabolites. Nuclear spin hyperpolarization techniques
can increase sensitivity in the MR experiment by
>10,000x. This has allowed us to image the location of
labeled cell substrates and, more importantly, their
metabolic conversion into other metabolites. We
showed that exchange of hyperpolarized 13C label
between lactate and pyruvate, in the reaction catalyzed
by the enzyme lactate dehydrogenase, could be imaged
in tumors and that this flux was decreased in treated
tumors undergoing drug-induced cell death [3]. We
compared this method for detecting treatment response
with measurements of fluorodeoxyglucose uptake [4].
We have shown, more recently, that hyperpolarized
[1,4-13C]fumarate can be used to detect tumor cell
necrosis post treatment [5]. We have also shown that
tissue pH can be imaged from the ratio of the signal
intensities of hyperpolarized H13CO3- and
13CO2 follow-
ing intravenous injection of hyperpolarized H13CO3-.
The technique was demonstrated with a study on a
mouse tumor model, which showed that the average
tumor pH was significantly lower than the surrounding
tissue. Since bicarbonate is already used intravenously in
humans, we propose that this technique could be used
clinically to image disease and response to treatment [6].
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